The vascular endothelial growth factor (VEGF) inhibitor bevacizumab is frequently used in treatment of primary CNS tumors as a steroid-sparing agent for management of symptomatic cerebral edema, even though it is not associated with an OS benefit [99]. This evidence concerns the gene VEGFA and brain edema.